The VICTOR trial is the largest phase 3 randomized study investigating vericiguat in chronic HFrEF patients without recent worsening events.
Vericiguat did not significantly reduce the composite endpoint of cardiovascular death or heart failure hospitalization compared to placebo in this population.
Notably, vericiguat was associated with a nominal reduction in cardiovascular and all-cause mortality.
The safety profile was consistent with previous vericiguat studies, with symptomatic hypotension more frequent but serious adverse events comparable to placebo.
